Yantai Dongcheng Pharmaceutical Co Ltd (002675) - Net Assets
Based on the latest financial reports, Yantai Dongcheng Pharmaceutical Co Ltd (002675) has net assets worth CN¥5.40 Billion CNY (≈ $790.83 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.18 Billion ≈ $1.34 Billion USD) and total liabilities (CN¥3.77 Billion ≈ $552.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Yantai Dongcheng Pharmaceutical Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.40 Billion |
| % of Total Assets | 58.88% |
| Annual Growth Rate | 28.53% |
| 5-Year Change | 12.58% |
| 10-Year Change | 83.4% |
| Growth Volatility | 56.45 |
Yantai Dongcheng Pharmaceutical Co Ltd - Net Assets Trend (2008–2025)
This chart illustrates how Yantai Dongcheng Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Yantai Dongcheng Pharmaceutical Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Yantai Dongcheng Pharmaceutical Co Ltd (2008–2025)
The table below shows the annual net assets of Yantai Dongcheng Pharmaceutical Co Ltd from 2008 to 2025. For live valuation and market cap data, see Yantai Dongcheng Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.66 Billion ≈ $827.65 Million |
+5.30% |
| 2024-12-31 | CN¥5.37 Billion ≈ $786.01 Million |
-0.45% |
| 2023-12-31 | CN¥5.40 Billion ≈ $789.55 Million |
+2.14% |
| 2022-12-31 | CN¥5.28 Billion ≈ $772.97 Million |
+5.15% |
| 2021-12-31 | CN¥5.02 Billion ≈ $735.14 Million |
+1.17% |
| 2020-12-31 | CN¥4.97 Billion ≈ $726.63 Million |
+3.91% |
| 2019-12-31 | CN¥4.78 Billion ≈ $699.31 Million |
+3.65% |
| 2018-12-31 | CN¥4.61 Billion ≈ $674.68 Million |
+40.19% |
| 2017-12-31 | CN¥3.29 Billion ≈ $481.25 Million |
+6.64% |
| 2016-12-31 | CN¥3.08 Billion ≈ $451.28 Million |
+37.93% |
| 2015-12-31 | CN¥2.24 Billion ≈ $327.19 Million |
+88.80% |
| 2014-12-31 | CN¥1.18 Billion ≈ $173.30 Million |
+7.53% |
| 2013-12-31 | CN¥1.10 Billion ≈ $161.16 Million |
+8.45% |
| 2012-12-31 | CN¥1.02 Billion ≈ $148.60 Million |
+233.59% |
| 2011-12-31 | CN¥304.42 Million ≈ $44.55 Million |
+59.33% |
| 2010-12-31 | CN¥191.06 Million ≈ $27.96 Million |
+36.05% |
| 2009-12-31 | CN¥140.43 Million ≈ $20.55 Million |
+76.99% |
| 2008-12-31 | CN¥79.34 Million ≈ $11.61 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Yantai Dongcheng Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8775.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.50 Billion | 34.40% |
| Common Stock | CN¥824.60 Million | 18.96% |
| Other Comprehensive Income | CN¥329.22 Million | 7.57% |
| Other Components | CN¥1.70 Billion | 39.08% |
| Total Equity | CN¥4.35 Billion | 100.00% |
Yantai Dongcheng Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Yantai Dongcheng Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
$1.54 Billion |
|
Qisda Corp
TW:2352
|
$1.54 Billion |
|
Devyani International Limited
NSE:DEVYANI
|
$1.54 Billion |
|
Minera Valparaiso S.A.
SN:MINERA
|
$1.54 Billion |
|
Beijing Lier High Temperature Materials Co Ltd
SHE:002392
|
$1.53 Billion |
|
Healthcare Services Group Inc
NASDAQ:HCSG
|
$1.53 Billion |
|
DOMS Industries Limited
NSE:DOMS
|
$1.53 Billion |
|
Domain Holdings Australia Limited
F:3DH
|
$1.53 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yantai Dongcheng Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,480,445,000 to 4,350,054,961, a change of -130,390,039 (-2.9%).
- Net income of 195,628,901 contributed positively to equity growth.
- Dividend payments of 24,737,871 reduced retained earnings.
- Other comprehensive income increased equity by 35,139,032.
- Other factors decreased equity by 336,420,101.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥195.63 Million | +4.5% |
| Dividends Paid | CN¥24.74 Million | -0.57% |
| Other Comprehensive Income | CN¥35.14 Million | +0.81% |
| Other Changes | CN¥-336.42 Million | -7.73% |
| Total Change | CN¥- | -2.91% |
Book Value vs Market Value Analysis
This analysis compares Yantai Dongcheng Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 36.73x to 2.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.35 | CN¥12.72 | x |
| 2009-12-31 | CN¥0.43 | CN¥12.72 | x |
| 2010-12-31 | CN¥0.49 | CN¥12.72 | x |
| 2011-12-31 | CN¥0.78 | CN¥12.72 | x |
| 2012-12-31 | CN¥2.19 | CN¥12.72 | x |
| 2013-12-31 | CN¥2.10 | CN¥12.72 | x |
| 2014-12-31 | CN¥2.25 | CN¥12.72 | x |
| 2015-12-31 | CN¥3.27 | CN¥12.72 | x |
| 2016-12-31 | CN¥4.16 | CN¥12.72 | x |
| 2017-12-31 | CN¥4.13 | CN¥12.72 | x |
| 2018-12-31 | CN¥5.52 | CN¥12.72 | x |
| 2019-12-31 | CN¥5.35 | CN¥12.72 | x |
| 2020-12-31 | CN¥5.57 | CN¥12.72 | x |
| 2021-12-31 | CN¥5.48 | CN¥12.72 | x |
| 2022-12-31 | CN¥5.88 | CN¥12.72 | x |
| 2023-12-31 | CN¥5.79 | CN¥12.72 | x |
| 2024-12-31 | CN¥5.43 | CN¥12.72 | x |
| 2025-12-31 | CN¥5.28 | CN¥12.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yantai Dongcheng Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.19%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 2.13x
- Recent ROE (4.50%) is below the historical average (10.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 19.85% | 4.66% | 1.66x | 2.57x | CN¥7.48 Million |
| 2009 | 22.81% | 8.50% | 1.41x | 1.90x | CN¥17.97 Million |
| 2010 | 26.53% | 7.63% | 1.85x | 1.88x | CN¥31.55 Million |
| 2011 | 42.05% | 14.92% | 1.90x | 1.48x | CN¥97.51 Million |
| 2012 | 10.35% | 17.87% | 0.54x | 1.07x | CN¥3.51 Million |
| 2013 | 9.27% | 13.02% | 0.63x | 1.13x | CN¥-7.93 Million |
| 2014 | 8.89% | 13.84% | 0.54x | 1.19x | CN¥-12.94 Million |
| 2015 | 4.38% | 11.29% | 0.31x | 1.24x | CN¥-115.05 Million |
| 2016 | 4.73% | 11.30% | 0.27x | 1.54x | CN¥-145.82 Million |
| 2017 | 5.95% | 10.82% | 0.30x | 1.82x | CN¥-117.62 Million |
| 2018 | 6.70% | 12.02% | 0.33x | 1.67x | CN¥-137.94 Million |
| 2019 | 3.60% | 5.17% | 0.41x | 1.70x | CN¥-274.56 Million |
| 2020 | 9.35% | 12.22% | 0.46x | 1.65x | CN¥-29.07 Million |
| 2021 | 3.45% | 3.87% | 0.51x | 1.74x | CN¥-288.18 Million |
| 2022 | 6.47% | 8.58% | 0.44x | 1.72x | CN¥-167.58 Million |
| 2023 | 4.39% | 6.40% | 0.41x | 1.69x | CN¥-267.80 Million |
| 2024 | 4.10% | 6.41% | 0.33x | 1.93x | CN¥-264.22 Million |
| 2025 | 4.50% | 7.19% | 0.29x | 2.13x | CN¥-239.38 Million |
Industry Comparison
This section compares Yantai Dongcheng Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,988,841
- Average return on equity (ROE) among peers: 4.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yantai Dongcheng Pharmaceutical Co Ltd (002675) | CN¥5.40 Billion | 19.85% | 0.70x | $1.53 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Yantai Dongcheng Pharmaceutical Co Ltd
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti… Read more